Rifampin in initial treatment of pulmonary tuberculosis. A U.S. Public Health Service tuberculosis therapy trial.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002986:Clinical Trials as Topic; D004977:Ethambutol / Q000008:administration & dosage*; D005260:Female; D006760:Hospitalization; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage*; D007958:Leukocyte Count; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D010146:Pain / Q000139:chemically induced; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects; D013307:Streptomycin / Q000008:administration & dosage*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014481:United States; D014492:United States Public Health Service; D014717:Vertigo / Q000139:chemically induced
D004977:Ethambutol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin